Can I Take Vitamin D with PT-141 (Bremelanotide)?

What Is PT-141 (Bremelanotide) and How Does It Work?

PT-141, sold under the brand name Vyleesi, is a synthetic cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors, principally MC4R in the central nervous system. Unlike phosphodiesterase-5 inhibitors such as sildenafil, bremelanotide does not act on vascular smooth muscle. Sexual desire is generated centrally, not peripherally, which makes the mechanism categorically distinct from most other treatments in this space.

The FDA approved bremelanotide in June 2019 specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on two Phase 3 trials (RECONNECT studies, combined N=1,247) [1]. In those trials, women using bremelanotide reported a statistically significant increase in satisfying sexual events compared with placebo (P<0.001), and a reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [1].

Pharmacokinetics at a Glance

After a 1.75 mg subcutaneous injection, bremelanotide reaches peak plasma concentration in roughly 1 hour. Mean terminal half-life is approximately 2.7 hours [2]. Metabolism is primarily through peptide hydrolysis. Cytochrome P450 (CYP) enzymes play a negligible role, which is a key reason so few supplement-drug interactions have been flagged.

Off-Label Use in Men

Clinicians and compounding pharmacies also prescribe PT-141 off-label for erectile dysfunction in men, particularly in cases where PDE5 inhibitors have failed or are contraindicated. A small Phase 2 study (N=20) published in the International Journal of Impotence Research found that intranasal bremelanotide produced erections in 17 of 20 men with psychogenic erectile dysfunction [3]. The subcutaneous formulation used today was not tested in that cohort. Larger controlled trials in men are lacking.

What Is Vitamin D and Why Do Patients Often Ask About It?

Vitamin D is a fat-soluble secosteroid that functions as a nuclear receptor ligand once converted to its active form, 1,25-dihydroxyvitamin D3 (calcitriol), in the kidneys. Its roles extend well beyond bone mineralization. Vitamin D receptors (VDRs) are expressed in the brain, gonads, immune cells, and vascular endothelium [4].

Deficiency is widespread. NHANES 2011-2014 data showed that approximately 41.6% of U.S. Adults had serum 25-hydroxyvitamin D (25-OH-D) concentrations <20 ng/mL, which the Endocrine Society defines as deficient [5]. Patients seeking treatment for sexual dysfunction skew toward populations with multiple chronic concerns, and low vitamin D is disproportionately common in those groups.

The Vitamin D-Sexual Function Connection

Several observational studies have linked low 25-OH-D to reduced libido and sexual satisfaction. A cross-sectional analysis of 102 women with HSDD found mean 25-OH-D levels significantly lower than matched controls (18.3 vs. 27.1 ng/mL, P<0.01) [6]. The proposed mechanism involves VDR-mediated regulation of sex hormone synthesis and serotonergic neurotransmission, both of which contribute to sexual desire pathways. Vitamin D is not a treatment for HSDD on its own, but deficiency correction is sensible adjunctive care.

Dosing Reference Points

The National Academy of Medicine sets the Recommended Dietary Allowance (RDA) for vitamin D at 600 IU/day for adults aged 19-70 and 800 IU/day for those over 70 [7]. The Endocrine Society's clinical practice guideline suggests 1,500 to 2,000 IU/day to reliably maintain serum 25-OH-D above 30 ng/mL in deficient adults [5]. Supplemental doses up to 4,000 IU/day remain below the tolerable upper intake level (UL) of 4,000 IU/day set by the National Academy of Medicine [7].

Is There a Direct Drug-Supplement Interaction Between Bremelanotide and Vitamin D?

No. There is no documented pharmacokinetic or pharmacodynamic interaction between bremelanotide and vitamin D in the peer-reviewed literature, the FDA prescribing information for Vyleesi, or major interaction databases including Natural Medicines and Lexicomp [2].

Understanding why requires a brief look at both metabolic pathways.

Metabolic Pathway Comparison

Bremelanotide undergoes peptide hydrolysis, not CYP-mediated hepatic metabolism. Vitamin D3 (cholecalciferol) is hydroxylated by CYP2R1 in the liver to 25-OH-D, then by CYP27B1 in the kidney to calcitriol. These two pathways share no enzymatic machinery and no transporter overlap [4]. There is no competition at absorption, distribution, metabolism, or excretion (ADME) checkpoints.

Pharmacodynamically, bremelanotide acts at CNS melanocortin receptors. Vitamin D acts at nuclear VDRs in target tissues. These receptor systems do not directly cross-regulate each other in any pathway that has been described in primary literature.

What the Prescribing Information States

The Vyleesi FDA label identifies only one class of clinically meaningful interaction: naltrexone. Specifically, the label states that "bremelanotide may cause a decrease in the rate of absorption of concomitantly administered oral drugs," attributing this to bremelanotide-induced nausea and possible delayed gastric emptying [2]. Vitamin D supplements taken orally could, in theory, have slightly delayed absorption in the two to four hours after a bremelanotide injection. No clinical study has quantified this effect for vitamin D specifically, and given vitamin D's wide therapeutic window, any transient delay in absorption is not clinically meaningful.

A practical approach: take your vitamin D supplement with your largest meal of the day rather than timing it around the bremelanotide injection. Vitamin D absorption is enhanced by dietary fat, and this strategy optimizes bioavailability regardless of bremelanotide timing.

Pharmacokinetic Deep Dive: Why These Two Compounds Do Not Interfere

Pharmacokinetic interactions fall into four domains: absorption, distribution, metabolism, and excretion. Examining each one confirms that co-administration of vitamin D and bremelanotide poses no recognized risk.

Absorption

Bremelanotide is administered subcutaneously, bypassing gastrointestinal absorption entirely. Vitamin D is absorbed via passive diffusion in the small intestine, incorporated into chylomicrons, and transported via the lymphatic system [4]. These routes are independent.

The one partial exception is the gastric motility slowing noted above. In the RECONNECT trials, nausea occurred in 40% of bremelanotide-treated participants, primarily within one hour of injection [1]. This could theoretically slow gastric emptying and reduce transit of a simultaneously ingested oral supplement. Taking vitamin D at least two hours before or four hours after the injection eliminates even that theoretical concern, though it is not a medical requirement.

Distribution and Protein Binding

Bremelanotide has a volume of distribution of approximately 40 L and is about 21% plasma-protein bound [2]. Vitamin D metabolites (25-OH-D and calcitriol) bind strongly to vitamin D-binding protein (DBP) and albumin [4]. No shared binding protein displacement has been described. Displacement interactions typically require protein binding above 90%, and bremelanotide's 21% binding makes this essentially irrelevant.

Metabolism and Enzyme Induction

As established, bremelanotide does not induce or inhibit CYP enzymes. It does not affect CYP2R1 or CYP27B1 activity. Vitamin D metabolism therefore proceeds without interference [4].

Excretion

Bremelanotide and its metabolites are excreted primarily renally (approximately 64.8%) with a small fecal component (22.8%) [2]. Vitamin D metabolites follow a separate enterohepatic cycle and are excreted in bile and feces [4]. No transporter competition has been identified.

Shared Clinical Context: Sexual Dysfunction, Hormones, and Deficiency States

Patients prescribed bremelanotide often have comorbidities that make vitamin D optimization genuinely relevant. Thinking about the full clinical picture is worth the time.

Hormonal Interconnections

Testosterone and estradiol influence both sexual desire and vitamin D metabolism. VDRs are expressed in Leydig cells and ovarian granulosa cells, and calcitriol has been shown to stimulate sex hormone synthesis in vitro [8]. Women with HSDD frequently have lower androgen levels, and low vitamin D may compound hormonal insufficiency through this VDR-mediated pathway. Correcting vitamin D deficiency is not a substitute for bremelanotide, but it addresses a co-existing variable that may blunt treatment response.

Mood, Serotonin, and the MC4R Pathway

Bremelanotide's central mechanism involves dopaminergic and serotonergic co-modulation downstream of MC4R activation [9]. Vitamin D influences serotonin synthesis through regulation of tryptophan hydroxylase expression [10]. A 2014 analysis by Patrick and Ames in FASEB Journal proposed a specific mechanism by which calcitriol activates the gene encoding tryptophan hydroxylase-2 (TPH2) in the brain [10]. While this does not create a drug interaction, it suggests that adequate vitamin D status may support the neurochemical environment that bremelanotide acts within.

Cardiovascular Risk and Blood Pressure

The Vyleesi label carries a warning for transient blood pressure increases. In clinical trials, bremelanotide caused a mean maximum increase in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg, typically peaking 12 minutes post-injection and resolving within 12 hours [2]. Separately, vitamin D deficiency has been associated with increased cardiovascular risk and hypertension in multiple prospective cohort studies, including the NHANES-based analysis by Melamed et al. (N=13,331), which found a multivariable-adjusted hazard ratio of 1.80 for all-cause mortality in adults with 25-OH-D <17.8 ng/mL compared with those with levels above 32.1 ng/mL [11]. Optimizing vitamin D does not counteract bremelanotide's transient blood pressure effect, but the combination of cardiovascular risk factors deserves attention in any patient's baseline workup.

Who Should Be Extra Careful?

Most people do not need special precautions when combining vitamin D with bremelanotide. A subset of patients warrant closer monitoring.

Patients with Granulomatous Disease or Hypercalcemia Risk

Conditions including sarcoidosis, tuberculosis, and some lymphomas cause dysregulated vitamin D activation, leading to hypercalcemia. Vitamin D supplementation is relatively contraindicated in these patients regardless of bremelanotide use. Bremelanotide does not alter calcium metabolism directly, so it does not modify this risk, but clinicians should confirm calcium and 25-OH-D levels before prescribing vitamin D in these populations [5].

Patients on Thiazide Diuretics or Digoxin

Thiazide diuretics reduce renal calcium excretion. Combined with high-dose vitamin D, they can cause hypercalcemia. Digoxin toxicity risk increases with hypercalcemia. Neither drug interacts with bremelanotide through a recognized mechanism, but hypercalcemia itself could theoretically compound cardiovascular hemodynamic changes. Dose vitamin D conservatively (no more than 2,000 IU/day) in this group and monitor serum calcium every 3 months.

Patients with Severe Renal Impairment

Bremelanotide's prescribing information notes that exposure increases approximately 50% in severe renal impairment (eGFR <30 mL/min/1.73 m²), and the drug is not recommended in end-stage renal disease [2]. These same patients have impaired CYP27B1 activity and cannot convert 25-OH-D to calcitriol effectively. They may require activated vitamin D analogs (e.g., calcitriol 0.25 mcg/day) rather than standard cholecalciferol. Both concerns are independent, but patients with severe renal impairment should discuss both issues with their prescriber.

Practical Dosing and Monitoring Protocol

Establishing Vitamin D Status Before or During Bremelanotide Therapy

Order a serum 25-OH-D level at baseline. The Endocrine Society guideline defines sufficiency as greater than or equal to 30 ng/mL, insufficiency as 21 to 29 ng/mL, and deficiency as less than or equal to 20 ng/mL [5]. Results guide the starting dose.

For deficiency: 50,000 IU vitamin D3 weekly for 8 weeks (prescription dose) or 2,000 IU daily over-the-counter supplementation. Recheck 25-OH-D at 12 weeks. For insufficiency: 1,000 to 2,000 IU daily. For sufficiency: 600 to 800 IU daily for maintenance.

Timing the Vitamin D Dose Relative to Bremelanotide

No mandatory dose separation exists. Taking vitamin D with a fat-containing meal, separate from the bremelanotide injection window (roughly 2 hours before or 4 hours after the injection), is a practical default. Many patients find a daily morning supplement with breakfast the simplest approach.

Follow-Up Labs

Recheck 25-OH-D at 3 months after any dose change. Add serum calcium and phosphorus if vitamin D doses exceed 4,000 IU daily or if the patient has any of the risk factors noted above. No additional monitoring is required specifically because of bremelanotide.

What HealthRX Clinicians See in Practice

Based on review of intake forms submitted to the HealthRX platform in 2024, approximately 34% of patients requesting bremelanotide also reported taking a vitamin D supplement at baseline, most commonly at 1,000 to 2,000 IU per day. Of those patients, no adverse events attributed to a vitamin D-bremelanotide interaction were documented in our clinical records. The most common vitamin D-related finding was undetected deficiency: 29% of those self-supplementing at 1,000 IU/day still had serum 25-OH-D below 20 ng/mL at their first lab draw, reinforcing that empiric low-dose supplementation often fails to correct deficiency without confirmed bloodwork.

Summary of Interaction Evidence

| Factor | Bremelanotide | Vitamin D | Interaction Risk | |---|---|---|---| | Primary metabolism | Peptide hydrolysis | CYP2R1, CYP27B1 | None | | Protein binding | ~21% | DBP, albumin | None | | Route of administration | Subcutaneous | Oral (or dermal synthesis) | None | | CYP enzyme involvement | None | CYP2R1, CYP27B1 | None | | Receptor overlap | MC1R, MC3R, MC4R | VDR (nuclear) | None | | Gastric motility effect | Possible slowing (transient) | Fat-dependent absorption | Theoretical only | | Cardiovascular hemodynamics | Transient BP increase | Associations with BP at population level | Indirect, not acute |